Compare WEST & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | ARVN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | 1393 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 773.6M | 658.2M |
| IPO Year | N/A | 2018 |
| Metric | WEST | ARVN |
|---|---|---|
| Price | $7.96 | $8.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | $7.00 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 1.0M | 815.8K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $11.27 | N/A |
| Revenue Next Year | $10.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.59 | $6.06 |
| 52 Week High | $8.98 | $14.22 |
| Indicator | WEST | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 27.27 |
| Support Level | $7.73 | $7.35 |
| Resistance Level | $8.98 | $8.22 |
| Average True Range (ATR) | 0.48 | 0.43 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 19.23 | 0.99 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.